ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > infomercial

<< Previous

Bullboard Posts

Next >>

Comment by garygpon Feb 27, 2024 2:50pm

133 Views

Post# 35902078

RE:infomercial

M101

You could use any one of your above noted chapters and write a compelling story on the abuse shareholders have taken at the hands of all BOD members over the past 20 years.

But, what the he!!. Use all four ideas and go for Best Seller status at the bookstores. I don't believe ProMIS are known in any pharmaceutical circles, certainly none that follow. Goldstein did a wonderful job in burying ProMIS and Farfel stole and put into hiding the grave maker forever.

gp

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement